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1. Introduction
The exploration of chemical space is an enduring chal-
lenge associated with the discovery of functional small
molecules. To address this challenge, synthetic methods need
to enable the exploration of diverse and novel molecular
property space that is relevant to the specific discovery
application in question. Guidelines have been formulated to
help steer chemists towards property space that is relevant to
particular classes of functional small molecules, including
drugs[1] and agrochemicals.[2] In spite of this, the synthetic
toolkit that currently dominates molecular discovery is
remarkably narrow,[3] which not only contributes to our
collective unsystematic and uneven
exploration of chemical space,[4] but
can also drive discovery away from
optimal property space![3a]
Recent high-profile articles auth-
ored by industrial scientists have chal-
lenged the academic community to
develop innovative synthetic methods
that align with future discovery needs.[5–10] In many cases,
compounds that would provide good starting points for
discovery have substantially different properties to those of
final optimized[1, 2] functional molecules, and specific attri-
butes of screening compounds,[5] fragments,[6] building
blocks,[7] and robust reactions[8] for drug discovery applica-
tions have been clearly described. Such articles can galvanize
the academic synthetic chemistry community. In addition,
major funded initiatives can facilitate the translation of
synthetic approaches developed in academia: for example,
the European Lead Factory has harnessed innovative syn-
thetic methods in the construction of its distinctive compound
collection.[11]
We argue, however, that in order to substantiate the
potential value of new synthetic methods for discovery
applications, it is necessary for researchers to demonstrate
that (and contextualize how) appropriate property space may
be targeted.[12] Although computational tools for library
enumeration and molecular property prediction are widely
used within industry, such tools are not yet widely used by the
academic synthetic chemistry community, with only limited
examples to date.[13]
Herein, we illustrate some of the limitations imposed by
the failure to appropriately benchmark substrate scope; we
demonstrate that simple and readily available computational
methods can help design thorough investigations of the scope
and limitations of new synthetic methods; and we show that
these analyses can help identify future applications of
emerging methods to support molecular discovery.
As our understanding of the impact of specific molecular properties
on applications in discovery-based disciplines improves, the extent to
which published synthetic methods meet (or do not meet) desirable
criteria is ever clearer. Herein, we show how the application of simple
(and in many cases freely available) computational tools can be used
to develop a semiquantitative understanding of the potential of new
methods to support molecular discovery. This analysis can, among
other things, inform the design of improved substrate scoping studies;
direct the prioritization of specific exemplar structures for synthesis;
and substantiate claims of potential future applications for new
methods.
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2. Demonstrating the Scope of Synthetic Methods:
Not All “R Groups” are Equal
The take-up of new synthetic methods by end-user
laboratories is, in part,[12] reliant on demonstrating that the
substrate scope is relevant to discovery applications. For
example, studies should ideally demonstrate that a new
method is compatible with substrates bearing heterocyclic
and functionalized substituents, in addition to carbocyclic and
unfunctionalized variants. In many array syntheses, the
presence of polar functionality in reactants or reagents
correlates strongly with unsuccessful reactions, due either to
intrinsic failure of the chemistry or to purification issues.
Arrays of produced compounds hence tend to be systemati-
cally less polar than designed, an undesirable outcome termed
“logP drift”.[5] An unrepresentative focus on specific struc-
tural features such as particular aromatic regioisomers can
also cause unanticipated issues. For example, a historic bias
towards p-substitution has been observed in medicinal
chemistry, which tends to reduce the three-dimensionality of
the possible products.[4b]
To illustrate the bias in the reported substrate scope of
new reactions within the published literature, we analyzed the
synthetic methodology papers that appeared in the first issues
of Angew. Chem. Int. Ed. (23 papers) and J. Am. Chem. Soc.
(6 papers) in 2016 (Figure 1). Specifically, we recorded the
range of variable aryl and hetaryl groups that had been
reported.
Some trends were apparent. First, the variation of
(substituted) phenyl groups tends to be investigated much
more thoroughly than that of hetaryl groups (Figure 1A).
Second, there are relatively few examples in which the
introduced (het)aryl group bears functionalizable handles
(such as halides, (protected) amines and alcohols, carbonyl
and carboxyl groups, and boronic acid derivatives; Fig-
ure 1B). Finally, the introduction of p-substituted phenyl
rings is demonstrated much more frequently than other
substitution patterns (Figure 1C), paralleling historic medic-
inal chemistry investigations.[4b]
The prominence of particular types of substituent may
accurately describe the actual scope of the synthetic method,
or may simply reflect the fact that a limited range of
substrates was investigated experimentally. To distinguish
between these possibilities, we suggest that best practice of
researchers should be to routinely investigate a wider range of
substrates, and that all unsuccessful examples should be
reported (for example, in the Supporting Information). Of
course, coupled with this, reviewers will need to regard the
reporting of such “negative” results not necessarily as
a limitation of the reported method, but rather as adding
value to the reader and prospective end user, and indeed as
a spur for future developments and improvements to existing
methods. In the course of the above analysis, despite the
undesirable bias in the variable groups reported when viewed
in aggregate, there were some examples of good practice, for
example, a new method for a-(het)arylation of a-amino-
methyltrifluoroborates using dual Ir/Ni catalysis, in which
a very wide range of substituted aryl and hetaryl groups
was explored (25% heteroaryl; > 60% functionalizable).[14]
More generally, we note that Glorius and Collins have
described a very useful screening approach that can help
identify robust reactions that are particularly tolerant of
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Figure 1. Reported variable groups in synthetic methodology papers in
the first issues in 2016 of Angew. Chem. Int. Ed. and J. Am. Chem. Soc.
(see the Supporting Information). A) Variation in terms of aryl and
hetaryl substitution. B) The proportion of functionalizable (het)aryl
versus unfunctionalizable (het)aryl groups incorporated. C) Variation
of phenyl substitution. Charts are scaled according to the number of
examples in the data set [504 examples for (A) and (B), 321 examples
for (C)].
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a broad range of functional groups,[15] which is now being
adopted by others.[16]
Given the apparent unsystematic exploration (or report-
ing) of molecular property space in many published studies,
we demonstrate below how computational tools may facilitate
the design of thorough analyses of the scope of new synthetic
methods.
3. Aligning Emerging Synthetic Methods with
Specific Discovery Applications
The identification of potential applications of new syn-
thetic methods may be facilitated by computational tools for
the enumeration and analysis of virtual libraries. Herein, we
have used our open-access computational tool Lead Likeness
And Molecular Analysis (LLAMA);[17] however, other open-
access tools (e.g., KNIME)[18] and many commercial tools are
also available. Such tools could also be used by synthetic
chemistry researchers to select reactants that allow the full
scope of their methods to be demonstrated. In most cases, we
used a standard set of typical medicinal chemistry capping
groups to decorate the scaffolds (see the Supporting Infor-
mation). Herein, we highlight some recent exciting synthetic
methods and provide evidence to suggest that they have the
potential to drive the discovery of different classes of
functional small molecules. For clarity, our analyses focus on
specific combinations of molecular properties in each case to
demonstrate the point in question, though clearly in industrial
applications, the full range of relevant properties needs to be
considered. Attempts to capture performance against a range
of molecular property measures have been made, for example
in a CNS drug-likeness score,[19] a metric capturing the
chemical beauty of drugs,[20] and a lead-likeness penalty.[17]
3.1. Methods to Target Property Space Relevant to Discovery
Applications
As discussed in Section 2 above, it is highly desirable that
any presentation of a new synthetic method examines an
appropriately broad substrate set, for example in terms of
chemical functionality and substitution patterns, but signifi-
cant additional useful information can be garnered by
examining the properties of the product set as a whole. Willis
and co-workers have developed a novel synthesis of sulfona-
mides in which an organometallic reagent is reacted with
a sulfur dioxide equivalent (DABSO) to give a product that is
then directly reacted with an aqueous solution of an amine
under oxidative conditions (Figure 2A).[21] The method was
found to be implementable in array format, and using
a combination of 7 organometallic reagents and 10 amines,
the synthesis of 65 (of 70 possible) products was successfully
demonstrated. The diverse range of functionalized substrates
used in this investigation was particularly notable.
The authorsQ own molecular property analysis suggested
that their method has the potential to support both drug and
agrochemical discovery. Our analysis (Figure 2B) confirms
that all of the array products have molecular weights and
calculated lipophilicities (AlogP) consistent with LipinskiQs
guidelines for orally bioavailable drugs. Moreover, a signifi-
cant proportion also have molecular weights and lipophilic-
ities that meet ClarkeQs guidelines[2a] for insecticides (60% of
the compounds; 210,MW, 500 and 0.9, logP, 6.6), fun-
gicides (41% of the compounds; 210,MW, 380 and 1.4,
logP, 4.8), and herbicides (57% of the compounds; 230,
MW, 430 and 0.7, logP, 4.9). Whilst other molecular
properties are also relevant in drug and agrochemical
discovery, this simple analysis confirms the potential value
of the method to support future discovery needs.
3.2. Design of Investigations to Test the Scope and Limitations of
Synthetic Methods
Molecular property analyses could prospectively also be
used to design investigations into the scope and limitations of
new synthetic methods, for example by prioritizing those
substrate and reagent combinations that enable the most
representative examination of molecular property space. We
noted the virtues of WolfeQs Pd-catalyzed aminoarylation
reactions for the synthesis of diverse pyrrolidines 1 (Fig-
ure 3A).[22] Distinctively, the approach enables both the
synthesis of the scaffold and the introduction of a variable
substituent on carbon through the aryl halide component.
Figure 2. Willis’ approach to the synthesis of sulfonamides from
organometallic reagents, DABSO, and amines.[21] A) Synthesis of an
exemplar sulfonamide. B) Molecular properties of the products of an
array of 7 organometallic reagents and 10 amines described in the
paper. The property space corresponding to Lipinski’s guidelines for
orally bioavailable drugs (dashed grey line), and Clarke’s parameters
for insecticides (black line), fungicides (solid grey line), and herbicides
(dashed black line) are indicated. DABSO is the bis-SO2 adduct of 1,4-
diazabicyclo[2.2.2]octane (DABCO).
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We sought to demonstrate the application of amino-
arylations to the synthesis of drug-relevant scaffolds. To guide
this study, we determined the molecular properties of virtual
libraries derived from the previously reported scaffold (1a) as
well as five related scaffolds that might also be prepared
(Figure 3B): in each case, the scaffolds were decorated once
with the set of exemplar capping groups. Notably, the mean
calculated lipophilicity of the derived libraries could be varied
enormously (ca. 3 AlogP units; Figure 3C) within the highly
structurally conserved series. We investigated the synthesis of
scaffolds 1d–f experimentally, and demonstrated that all
three scaffolds could be prepared in good (60–87%) yield and
with high diastereoselectivity.[13c] The synthetic approach was
subsequently exploited in the synthesis of more than 500
compounds that were added to the compound collection of
the European Lead Factory.
3.3. Identification of Novel Scaffolds for Drug Discovery
Applications
The ability to elaborate diverse, novel scaffolds for library
enrichment in a synthetically efficient manner is a significant
challenge. Bode and co-workers have developed SnAP
reagents that enable the synthesis of structurally diverse
heterocycles from aldehydes or ketones (Figure 4).[23] As an
example, condensation of the amino-substituted stannane 2a
with benzaldehyde gives the corresponding morpholine 3a
(Figure 4A). A range of SnAP reagents (many commercially
available) has been described, each leading to distinctive
heterocyclic scaffolds. The potential value of the products as
building blocks for drug discovery has been noted.[24]
To demonstrate potential applications of the approach, we
considered a range of building blocks that might be prepared
by the combination of known SnAP reagents with benzalde-
hyde (Figure 4B). In each case, to complement the diversity
possible by varying the aldehyde reactant, the building blocks
were additionally decorated once using the exemplar capping
groups (see the Supporting Information). The molecular
properties of the resulting virtual libraries are shown in
Figure 4C.
We note that all of the scaffolds (3b–j) have at least some
derivatives with lead-like molecular properties.[5] However,
with the set of capping groups used, scaffolds 3b, 3c, 3 f, 3g,
and 3 i enable lead-like property space to be targeted most
effectively. Of course, the molecular properties of the
derivatives may be tuned by varying the specific aldehyde
and/or capping groups used. However, as others have
noted,[25] the presence of benzo-fused rings such as those in
3e and 3h have a very significant effect on the properties of
derivatives. In terms of molecular novelty, we noted that
(after virtual Boc deprotection) only 3b is found as a sub-
structure in a search of a random 2% selection from the
ZINC database. We conclude that the scaffolds 3c,d, 3 f, 3g,
and 3 i,j may enable significant novel regions of lead-like
property space to be explored.
Drug discovery against central nervous system (CNS)
targets raises the additional challenge of penetration of the
blood–brain barrier. The challenge is exacerbated in the
search for high-quality lead molecules, which generally need
to be both smaller and less lipophilic than the final drug
candidates.[5]
Marcaurelle and co-workers have described the synthesis
of a range of azetidine-based scaffolds (4–11) that were
designed to meet the needs of CNS drug discovery (Fig-
ure 5A).[26] We decorated each scaffold once using our
standard set of medicinal chemistry capping groups. To
Figure 3. Synthesis of 2,5-disubstituted pyrrolidines using Pd-catalyzed
aminoarylation reactions. A) Synthesis of pyrrolidine 1a, as reported by
Wolfe.[22a] B) Pyrrolidines that might also be accessible using the
method. C) Mean molecular properties of virtual libraries derived from
the scaffolds 1. In each case, the Boc group was removed and the
scaffold was decorated once using a range of standard capping
groups. Lipinski’s guidelines for orally bioavailable drugs are indicated
by the solid black line. Novel scaffolds (compared to a random 2%
selection of the ZINC database) are shown in black, whilst known
substructures are shown in grey. Standard deviations are indicated.
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establish relevance to CNS drug discovery, we assessed the
resulting virtual libraries against established guidelines for
CNS drugs (Figure 5B).[19] We note that 81% of the
compounds satisfied guidelines for both molecular size and
lipophilicity (AlogP, 3; heavy atoms, 26), whilst the rest of
the compounds fell into a transitional area (3<AlogP< 5 or
26, heavy atoms, 36). We also analyzed the molecular
properties of the compounds on a per-scaffold basis, and
concluded that, using our decoration strategy, the scaffolds 4–
6 and 9–11 allow CNS drug-like space to be targeted most
effectively. Marcaurelle and co-workers have also described
the pairwise decoration of 9 to yield more than 1900
compounds. The cell permeability of seven exemplar final
compounds were measured experimentally, confirming their
suitability for transport in the gut and at the blood–brain
barrier.
3.4. Establishing the Shape Diversity of sp3-Rich Small-Molecule
Libraries
Novel sp3-rich molecular scaffolds that combine well-
defined molecular topologies with functional-group handles
for diversification have been noted to have significant value in
drug discovery applications.[6, 7, 25a] However, the impact of
a scaffold on the three-dimensionality of its derivatives is
often not obvious by simple inspection. Carreira and Rogers-
Evans have developed efficient syntheses of small sp3-rich
spirocyclic scaffolds (such as 12 and 13 ; Figure 6A).[27] We
analyzed the diversity of molecular shapes that may be
Figure 4. Bode’s approach to nitrogen-containing heterocycles using
SnAP reagents.[23] A) Exemplar reaction of benzaldehyde with a SnAP
reagent. B) Additional scaffolds that have been, or might be, prepared
from benzaldehyde using the approach. C) Mean molecular properties
of virtual libraries derived from scaffolds 3 after one decoration
reaction. Novel scaffolds are shown in black, whilst those that are
found as substructures in a random 2% sample from the ZINC
database are shown in grey. Standard deviations are shown. Lead-like
molecular property space[5] is indicated by the black box.
Figure 5. Assessment of the relevance of scaffolds to CNS drug
discovery. A) The scaffolds considered in this study.[26] B) Mean molec-
ular properties of virtual libraries derived from the scaffolds 4–11 after
one decoration. Standard deviations are shown. Molecular property
space is shaded according to Pfizer’s guidelines for relevance to CNS
drug discovery (pale pink: optimal, dark pink: transitional area, red:
undesirable).[19]
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explored through decoration of these scaffolds. Similar
analyses could also be undertaken for other synthetic
approaches to diverse molecular scaffolds.[28]
We enumerated virtual libraries in which four scaffolds
12a/b and 13a/b were decorated once or twice with the
standard set of capping reagents. While there are several
metrics by which shape diversity can be assessed,[29,30] we used
principal moments of inertia (PMI) plots. PMIs were deter-
mined for a low-lying conformer of each compound, and the
mean PMIs for the compounds based on each scaffold are
presented in Figure 6B. We note that the shape of the
resulting compounds depends critically on the position of the
functionalizable groups within the scaffolds (and hence the
vectors that may be explored). Compounds derived from the
scaffolds 12a and 13a are systematically more linear than
those derived from the regioisomeric scaffolds 12b and 13b ;
however, the significant difference in mean PMIs between
scaffolds 12a and 13a (versus the closely aligned values for
12b/13b) is notable and could not have been predicted by
simple inspection.
Bull and co-workers have developed an efficient method
for the synthesis of diverse substituted oxetanes, which were
designed to explore three-dimensional fragment space (Fig-
ure 7).[31] As an example, Rh-catalyzed reaction of the diazo
compound 14 with the 2-bromo alcohol 15 gave the corre-
sponding O@H insertion product 16 ; subsequent base-medi-
ated cyclization gave the substituted oxetane 17a (Fig-
ure 7A).
To assess the potential value of the method to yield
distinctive fragments, we enumerated a virtual library of
amides by combining six deprotected scaffolds (Figure 7B)
with 28 small commercially available amines (see the
Supporting Information). 36% (61/168) of the virtual prod-
ucts had fragment-like properties (9, heavy atoms, 17;
@1,AlogP, 3). We compared the shapes of low-lying
conformers of these 61 fragments with those of 257 commer-
cially available fragments and 261 randomly chosen frag-
ments from the GDB-17 database of exhaustively enumer-
ated compounds (Figure 7C).[32] The GDB-17 database
provides an insight into the shape diversity of all possible
fragments; this potential diversity is poorly sampled by
commercially available fragments, which tend to lie close to
the rod–disk edge of a PMI plot. Our analysis shows that
BullQs scaffolds can be decorated to yield fragments that are
significantly more three-dimensional than commercially
available fragments.
4. Conclusions and Future Perspectives
We have demonstrated that simple, readily available
computational tools can be used to inform a semiquantitative
understanding of the likely value of new chemical methods to
Figure 6. Evaluation of the shape diversity of virtual libraries based on
spirocyclic scaffolds reported by Carreira and Rogers-Evans.[27] A) The
scaffolds evaluated in this study. B) Mean principal moments of inertia
of virtual libraries generated by decoration of the scaffolds once or
twice using the standard set of capping groups. See the Supporting
Information for further details.
Figure 7. Bull’s approach to substituted oxetanes.[31] A) Synthesis of an
exemplar oxetane (R=Bn, which was virtually removed before the
computational study). B) Other scaffolds that were combined with 28
small amines to yield a virtual library of amides (see the Supporting
Information). C) PMI plot of the 61 fragment-like compounds found in
the virtual library (black), 257 fragments randomly selected from the e-
molecules database (light gray) and 261 fragments randomly selected
from the GDB-17 database (dark gray). A plane-of-best-fit analysis
(Ref. [30]) is also provided in the Supporting Information.
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the discovery sciences. While examples of the retrospective
use of these tools are beginning to appear in the literature, we
argue that it is important that they are now used to ensure that
the scope and limitations of new methods are fully estab-
lished. The information from such analyses can be used,
among other things, to design suitably representative sub-
strate sets against which to test reactions, or to prioritize the
synthesis of “high-value” scaffolds from a range of possible
products. We argue (as have others in related contexts)[33] that
such an approach should not be regarded as a restriction, but
rather as a challenge and inspiration for the academic
synthetic chemistry community. A better, shared understand-
ing of the scope and limitations of new methods will
ultimately lead to more-rapid uptake of the most valuable
methods, thereby benefitting both the end-user community
(availability of trustworthy new tools) and the academic
authors (higher citation, demonstrable impact).
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